Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress
EbvalloTM Positioned to be the First Allogeneic T-Cell Therapy Ever Approved Following CHMP Positive Opinion New ATA188 Biomarker Imaging Data Show Less Brain Atrophy and Possible Remyelination in Patients Achieving Confirmed Disability Improvement in Progressive MS Phase 1 Study of ATA2271 Enrollment Resumed Conference Call and Webcast Today at 1:30 p.m. PST / 4:30 p.m. … [Read more…]
